Mineralys Enterprise Value from 2010 to 2024

MLYS Stock

12.49 0.62 5.22%

Mineralys Therapeutics, Enterprise Value yearly trend continues to be comparatively stable with very little volatility. Enterprise Value is likely to outpace its year average in 2024. Enterprise Value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization that includes the market capitalization, plus total debt, minority interest and preferred shares, minus total cash and cash equivalents. View All Fundamentals

Enterprise Value

First Reported

2010-12-31

Previous Quarter

765.6 M

Current Value

769.5 M

Quarterly Volatility

23 M

Credit Downgrade

Yuan Drop

Covid

Check Mineralys Therapeutics, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mineralys Therapeutics,'s main balance sheet or income statement drivers, such as Net Interest Income of 10.9 M, Depreciation And Amortization of 159.5 K or Interest Expense of 2 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.36. Mineralys financial statements analysis is a perfect complement when working with Mineralys Therapeutics, Valuation or Volatility modules.

Check out the analysis of Mineralys Therapeutics, Correlation against competitors.

Latest Mineralys Therapeutics,'s Enterprise Value Growth Pattern

Below is the plot of the Enterprise Value of Mineralys Therapeutics, Common over the last few years. Enterprise Value (or EV) is usually referred to as Mineralys Therapeutics, theoretical takeover price. In the event of an acquisition, an acquirer would have to take on Mineralys Therapeutics, debt, but would also pocket its cash. Enterprise Value is more accurate representation of Mineralys Therapeutics, value than its market capitalization because it takes into account all of Mineralys Therapeutics, Common existing debt. It is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization that includes the market capitalization, plus total debt, minority interest and preferred shares, minus total cash and cash equivalents. Mineralys Therapeutics,'s Enterprise Value historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Mineralys Therapeutics,'s overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 624.7 M

10 Years Trend

Pretty Stable

Compare to Others All Fundamentals

Enterprise Value

Timeline

Mineralys Enterprise Value Regression Statistics

	Arithmetic Mean	724,438,114
	Geometric Mean	724,094,734
	Coefficient Of Variation	3.17
	Mean Deviation	11,487,283
	Median	723,295,681
	Standard Deviation	22,997,596
	Sample Variance	528.9T
	Range	103.8M
	R-Value	0.16
	Mean Square Error	554.5T
	R-Squared	0.03
	Significance	0.56
	Slope	835,750
	Total Sum of Squares	7404.5T

Mineralys Enterprise Value History

	2024	769.5 M
	2023	765.6 M
	2022	665.7 M
	2021	709.6 M

Other Fundumenentals of Mineralys Therapeutics,

	Enterprise Value Over E B I T D A
	Enterprise Value Multiple

Mineralys Therapeutics, Enterprise Value component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Net Invested Capital	Short Long Term Debt	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt	Common Stock	Deferred Long Term Liab
Total Assets		0.9	-0.88	-0.8	-0.99	0.46	0.24	0.89	-0.9	1.0	0.95	1.0	-0.9	0.95	0.96
Total Stockholder Equity	0.9		-0.6	-0.45	-0.89	0.03	-0.22	1.0	-0.94	0.9	0.99	0.9	-0.94	0.99	0.75
Net Tangible Assets	-0.88	-0.6		0.97	0.89	-0.77	-0.63	-0.58	0.66	-0.88	-0.7	-0.88	0.66	-0.7	-0.95
Net Debt	-0.8	-0.45	0.97		0.79	-0.89	-0.77	-0.43	0.54	-0.79	-0.57	-0.8	0.54	-0.57	-0.92
Retained Earnings	-0.99	-0.89	0.89	0.79		-0.44	-0.23	-0.88	0.88	-0.99	-0.95	-0.99	0.88	-0.95	-0.95
Accounts Payable	0.46	0.03	-0.77	-0.89	-0.44		0.94	0.02	-0.23	0.45	0.17	0.46	-0.23	0.17	0.66
Total Liab	0.24	-0.22	-0.63	-0.77	-0.23	0.94		-0.23	0.08	0.23	-0.08	0.23	0.08	-0.08	0.47
Net Invested Capital	0.89	1.0	-0.58	-0.43	-0.88	0.02	-0.23		-0.94	0.89	0.99	0.89	-0.94	0.99	0.74
Short Long Term Debt	-0.9	-0.94	0.66	0.54	0.88	-0.23	0.08	-0.94		-0.9	-0.95	-0.9	1.0	-0.95	-0.79
Total Current Assets	1.0	0.9	-0.88	-0.79	-0.99	0.45	0.23	0.89	-0.9		0.95	1.0	-0.9	0.95	0.96
Capital Stock	0.95	0.99	-0.7	-0.57	-0.95	0.17	-0.08	0.99	-0.95	0.95		0.95	-0.95	1.0	0.83
Net Working Capital	1.0	0.9	-0.88	-0.8	-0.99	0.46	0.23	0.89	-0.9	1.0	0.95		-0.9	0.95	0.96
Short Term Debt	-0.9	-0.94	0.66	0.54	0.88	-0.23	0.08	-0.94	1.0	-0.9	-0.95	-0.9		-0.95	-0.79
Common Stock	0.95	0.99	-0.7	-0.57	-0.95	0.17	-0.08	0.99	-0.95	0.95	1.0	0.95	-0.95		0.83
Deferred Long Term Liab	0.96	0.75	-0.95	-0.92	-0.95	0.66	0.47	0.74	-0.79	0.96	0.83	0.96	-0.79	0.83

Click cells to compare fundamentals

About Mineralys Therapeutics, Financial Statements

Mineralys Therapeutics, shareholders use historical fundamental indicators, such as Enterprise Value, to determine how well the company is positioned to perform in the future. Although Mineralys Therapeutics, investors may analyze each financial statement separately, they are all interrelated. The changes in Mineralys Therapeutics,'s assets and liabilities, for example, are also reflected in the revenues and expenses on on Mineralys Therapeutics,'s income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Enterprise Value Over EBITDA	(3.09)	(3.25)
Enterprise Value Multiple	(3.09)	(3.25)
Enterprise Value	765.6 M	769.5 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Mineralys Stock Analysis

When running Mineralys Therapeutics,'s price analysis, check to measure Mineralys Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mineralys Therapeutics, is operating at the current time. Most of Mineralys Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Mineralys Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mineralys Therapeutics,'s price. Additionally, you may evaluate how the addition of Mineralys Therapeutics, to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC